Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on on healthcare or medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine. For up-to-date information on other healthcare topics, please consult the relevant reliable sources or an healthcare expert, such as a physician etc.
 BACK TO LIST

European Patient Summary

Patient
Name: Pocius, Kristina
DOB: 20-JAN-1944 (Age: 82)
Gender: male
ID: 5121-608381-9 (ECI)
Author
Kazlauskas, Žemyna
Patient summary Document
European Patient Summary
Report Date: 14-JUN-2025

Problem list

Condition Onset Date / Period Status
Alzheimer's disease 29-Jul-2023 active
Ischemic heart disease 09-Feb-2008 active
Osteoporosis 17-Jan-2004 active
Neuropathy due to type 2 diabetes mellitus 29-Sep-1984 active
Hyperglycemia 06-Sep-1980 active
Hypertriglyceridemia 06-Sep-1980 active
Type 2 diabetes mellitus 01-Sep-1979 active
Metabolic syndrome X 01-Sep-1979 active
Anemia 01-Sep-1979 active
Essential hypertension 17-Jul-1971 active
Chronic sinusitis 23-Mar-1953 active
Pneumonia 07-Mar-2021 - 16-Mar-2021 inactive
Hypoxemia 07-Mar-2021 - 16-Mar-2021 inactive
COVID-19 07-Mar-2021 - 16-Mar-2021 inactive
Acute infective cystitis 15-Mar-2020 - 16-Mar-2020 inactive
Acute bronchitis 25-Jan-2019 - 13-Feb-2019 inactive
Acute viral pharyngitis 19-Oct-2017 - 29-Oct-2017 inactive

Medication list

Medication Since Form Dosage Reason
Fentanyl 25 microgram/hour prolonged-release transdermal patch 2025-06-14 - 25 micrograms/hour transdermal patch applied every 72 hours -
Amlodipine (as amlodipine besylate) 2.5 mg oral tablet 2025-06-14 - 1 tablet (2.5 mg) by mouth once daily Essential hypertension (disorder)
Tramadol hydrochloride 50 mg oral tablet 2025-06-14 - 1 tablet (50 mg) every 6 hours as needed -
Acetaminophen 300 mg and hydrocodone bitartrate 5 mg oral tablet 2025-06-14 - 1 tablet (300 mg/5 mg) by mouth every 4 to 6 hours as needed for pain -
Metformin hydrochloride 500 mg prolonged-release oral tablet 2025-06-14 - 1 tablet (500 mg) once daily Diabetes mellitus type 2 (disorder)
Alendronic acid (as alendronate sodium) 10 mg oral tablet 2025-06-14 - 1 tablet (10 mg) once daily Osteoporosis (disorder)
Oxycodone hydrochloride 10 mg prolonged-release oral tablet 2025-06-14 - 1 tablet (10 mg) every 12 hours -
Galantamine (as galantamine hydrobromide) 4 mg oral tablet 2023-07-29 - 4 mg twice daily Alzheimer's disease (disorder)
Clopidogrel (as clopidogrel bisulfate) 75 mg oral tablet 2008-02-16 - 1 tablet (75 mg) once daily -
Simvastatin 20 mg oral tablet 2008-02-16 - 1 tablet (20 mg) by mouth once daily -
Nitroglycerin 400 microgram/actuation sublingual spray 2008-02-16 - 1 spray (400 micrograms) under the tongue as needed for chest pain, may repeat every 5 minutes as needed, up to 3 sprays in 15 minutes -
Metoprolol tartrate (as metoprolol succinate) 100 mg prolonged-release oral tablet 2008-02-16 - 1 tablet (100 mg) once daily -
Vitamin B12 and/or vitamin B12 derivative-containing product 1979-09-08 - 1000 micrograms once daily -

Immunizations list

Vaccine Date
Influenza virus antigen only vaccine product 16-Nov-2024
Clostridium tetani toxoid antigen adsorbed only vaccine product 11-May-2024
SARS-CoV-2 mRNA vaccine 03-Apr-2021

Procedure History list

Procedure Date Reason
Assessment of health and social care needs 22-Feb-2025 -
Assessment using Morse Fall Scale 22-Feb-2025 -
Depression screening 20-Apr-2024 -
Screening for substance abuse 20-Apr-2024 -
Medication reconciliation 20-Apr-2024 -
Assessment of anxiety 20-Apr-2024 -
Screening for domestic abuse 20-Apr-2024 -
Assessment of substance use 20-Apr-2024 -
Referral to home health care service 03-Jul-2021 -
Oxygen administration by mask 16-Mar-2021 Hypoxemia (disorder)
Placing subject in prone position 16-Mar-2021 Hypoxemia (disorder)
Plain X-ray of chest 07-Mar-2021 -
Patient evaluation and management 15-Mar-2020 -
Urine specimen collection 15-Mar-2020 -
Patient discharge 15-Mar-2020 -
Taking patient vital signs 15-Mar-2020 -
History taking 15-Mar-2020 -
Discussion about signs and symptoms 15-Mar-2020 -
Antibiotic therapy 15-Mar-2020 -
Triage: emergency center 15-Mar-2020 -
Urinalysis with reflex to microscopy and culture 15-Mar-2020 -
Assessment using AUDIT-C (Alcohol Use Disorders Identification Test - Consumption) 16-Feb-2019 -

Allergies and Intolerances

No known allergies or intolerances

Care Plan

Active Planned Care / Goals Start Date Reason
Dementia management 29-Jul-2023 Alzheimer's disease (disorder)
  • Maintain current level of cognitive function and slow progression of cognitive decline associated with Alzheimer's disease
  • Support the patient to maintain independence in basic activities of daily living for as long as possible
  • Reduce frequency and severity of behavioral and psychological symptoms of dementia
  • Ensure consistent adherence to prescribed dementia medications to maximize therapeutic benefit
  • Provide resources and support to caregivers to reduce caregiver burden and improve quality of life
Therapy 23-Mar-2014 -
Diabetes self management plan 01-Sep-1979 Diabetes mellitus type 2 (disorder)
  • Maintain HbA1c at or below individualized target to optimize glycemic control and reduce complications.
  • Maintain blood pressure below 140/90 mmHg to reduce cardiovascular risk.
  • Maintain LDL cholesterol below 70 mg/dL to reduce cardiovascular risk.
  • Maintain fasting blood glucose between 80 and 130 mg/dL to optimize glycemic control.
  • Maintain triglycerides below 150 mg/dL to reduce cardiovascular risk.
Lifestyle education regarding hypertension 17-Jul-1971 Essential hypertension (disorder)
  • Achieve and maintain target blood pressure through lifestyle modifications.
Immunization Recommendation Due Date Reason
Influenza virus antigen only vaccine product 01-Oct-2026 Annual seasonal influenza vaccination

Vital Signs

Vital Signs 2025-06-14 2025-05-17
Body Height 179.2 cm 179.2 cm
Pain severity - 0-10 verbal numeric rating [Score] - Reported 0 {score} 2 {score}
Body Weight 89.9 kg 89.9 kg
Body mass index (BMI) [Ratio] 28 kg/m2 28 kg/m2
Heart rate 89 /min 91 /min
Respiratory rate 13 /min 13 /min
Blood pressure panel with all children optional 75 mm[Hg] 78 mm[Hg]

Relevant diagnostic tests/laboratory data

Recent Lab Observations 14-JUN-2025 Reference Range Unit
Hemoglobin A1c/Hemoglobin.total in Blood 5.5 4.8 - 5.9 %
Glucose [Mass/volume] in Blood 67.2 L 70 - 100 mg/dL
Urea nitrogen [Mass/volume] in Blood 7.1 7 - 20 mg/dL
Creatinine [Mass/volume] in Blood 0.7 0.6 - 1.3 mg/dL
Calcium [Mass/volume] in Blood 9.8 8.5 - 10.5 mg/dL
Sodium [Moles/volume] in Blood 138.7 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 5.1 3.5 - 5.3 mmol/L
Chloride [Moles/volume] in Blood 109.7 H 98 - 107 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 21.0 L 22 - 29 mmol/L
Cholesterol [Mass/volume] in Serum or Plasma 134.4 125 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 134.7 0 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 78.3 0 - 100 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 29.1 L 40 - 60 mg/dL
Microalbumin/Creatinine [Mass Ratio] in Urine 2.8 0 - 30 mg/g

Device Use

Device Date (since)
Blood glucose meter (physical object) 01-Sep-1979
Home nebulizer (physical object) 23-Mar-1953